Caitong International Asset Management
NKTR icon

Caitong International Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Caitong International Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,798
Closed -$129K – 3314
2026
Q1 		$129K Buy
+1,798
New +$102K 0.02% 508
2025
Q4 		– Sell
-11
Closed -$626 – 2243
2025
Q3 		$626 Buy
+11
New +$364 ﹤0.01% 1530

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caitong International Asset Management's NKTR Position: Q2 2026 in Review

Caitong International Asset Management sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 1,798 shares — an estimated $129K sold.

Caitong International Asset Management first reported a position in NKTR in Q3 2025 and held it in 2 quarters. The position peaked at $129K in Q1 2026. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Caitong International Asset Management reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Caitong International Asset Management sold 1,798 Nektar Therapeutics shares in Q2 2026, an estimated $129K.
  • Caitong International Asset Management first reported a position in Nektar Therapeutics in Q3 2025 and held it in 2 quarters.
  • Caitong International Asset Management's Nektar Therapeutics position peaked at $129K in Q1 2026.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.